Tag Archives: Administrator

An “Open Letter” to President Trump Regarding the Prescription Drug Abuse Epidemic

Dear President Trump, For several years the prescription drug epidemic has ravaged communities across the United States.  During that time, the Drug Enforcement Administration (“DEA”) has aggressively pursued enforcement actions against the regulated industry.  Despite admirable efforts to curtail the epidemic through enforcement actions, prescription drug abuse continues to be a public health crisis.  There … Continue Reading

DEA Prevails Over Masters Pharmaceutical, Inc.

On June 30, 2017, the Court of Appeals for the D.C. Circuit issued an order in Masters Pharmaceutical, Inc. v. Drug Enforcement Administration (No. 15-1335). In sum, the Court denied Masters Pharmaceutical, Inc.’s (“Masters”) Petition for Review seeking to overturn the Drug Enforcement Administration’s (“DEA”) revocation of Masters’ DEA registration. This decision has wide-ranging implications … Continue Reading

DEA Will Not Reschedule Marijuana

  Marijuana is less dangerous than some substances in other schedules, but it will stay in Schedule I for now, DEA said Thursday. The agency also said that it supports marijuana research, is developing an online application system to apply for Schedule I research registrations, and will allow more manufacturers to grow marijuana for research. … Continue Reading

The Continued Evolution of DEA’s Due Diligence Requirements

On May 11, 2016, the Drug Enforcement Administration filed its brief in Masters Pharmaceutical, Inc. v. Drug Enforcement Administration (Docket No: 15-1335), in the United States Court of Appeals for the District of Columbia. The vast majority of the Government’s brief addresses whether “substantial evidence” (the applicable standard of review) supports Acting Administrator Rosenberg’s decision … Continue Reading

DEA to Continue Take Back Programs

On September 23, 2014, DEA announced that its ninth Take Back Day would be the agency’s last.  The announcement was made shortly after DEA published the Final Rule implementing the Secure and Responsible Drug Disposal Act of 2010.  The regulations promulgated by DEA allow “authorized collectors” the opportunity to receive and securely dispose of prescription … Continue Reading

DEA Decisions: In the Matter of Moore Clinical Trials, L.L.C.

In the Matter of Moore Clinical Trials, L.L.C (July 11, 2014) DEA last month denied the DEA research registration application of an Arkansas clinical research company, finding that the person who would be primarily responsible for ordering and storing controlled substances had a “shocking” lack of knowledge of the fundamental requirements imposed by the Controlled … Continue Reading

DEA Decisions: In the Matter of Hoi Y. Kam, M.D.

In the Matter of Hoi Y. Kam, M.D. (October 22, 2013) In July 2011, the New York Department of Health revoked Dr. Hoi Kam’s medical license on the ground that he previously committed Medicaid fraud and had been excluded from the Medicaid program in 2006.  Three months later, however, the State’s Administrative Review Board (ARB) … Continue Reading

DEA Decisions: In the Matter of Gabriel Sanchez

In the Matter of Gabriel Sanchez, M.D. (September 25, 2013) On July 15 2010, Dr. Gabriel Sanchez issued prescriptions for oxycodone (Schedule II) and carisoprodol (Schedule IV) to two undercover law enforcement officers.  During the visits with both undercover officers, Dr. Sanchez failed to take complete medical histories, failed to make serious inquiries into the … Continue Reading

DEA Decisions: In the Matter of S&S Pharmacy, Inc., d/b/a Platinum Pharmacy & Compounding

In the Matter of S&S Pharmacy, Inc., d/b/a Platinum Pharmacy & Compounding (Sept. 19, 2013) In 2011, Ihab S. Barsoum, the owner and pharmacist-in-charge of S&S Pharmacy, Inc., d/b/a Platinum Pharmacy & Compounding (“Platinum Pharmacy”), engaged in what the Administrator described as “blatant drug deal(s) and [] distribution(s).”  On five occasions between January and June … Continue Reading

DEA Decisions: In the Matter of Kevin Dennis, M.D.

In the Matter of Kevin Dennis, M.D. (August 26, 2013) In 2007, Dr. Kevin Dennis became involved with an Internet prescribing company known as “Telemed Ventures.”  Between 2007 and 2008, Dr. Dennis (who was licensed and registered in Tennessee only) issued numerous prescriptions to individuals located in other states without seeing them or performing any … Continue Reading

DEA Decisions: In the Matter of Mireille Lalanne

In the Matter of Mireille Lalanne, M.D., 78 Fed. Reg. 47,750 (August 6, 2013) Dr. Lalanne is a physician who, sometime before November 2008, became involved in an organized crime scheme.  Her role?  Dr. Lalanne provided controlled substance prescriptions to different syndicates for illegal distribution.  In November 2008, Dr. Lalanne was indicted by a Kentucky … Continue Reading
LexBlog